EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report

Yangyang Zhang, Qi Yu, Yan Liu, Yiyuan Yuan, Yanlang Yang

Frontiers in Medicine · 18.11.2026 · 13

DOI: 10.3389/fmed.2026.2011766 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 18.11.2026. Verfasst von Yangyang Zhang und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IgA vasculitis nephritis (IgAVN) with podocyte injury is a treatment-refractory subtype of IgA vasculitis that often responds poorly to glucocorticoids and is accompanied by persistent proteinuria. New-onset IgAVN during interleukin-17A (IL-17A) inhibitor therapy in patients with ankylosing spondylitis (AS) is extremely rare. Case presentation A 24-year-old, HLA-B27–positive man with axial-predominant AS on long-term secukinumab developed palpable purpura after an influenza virus infection, followed by hematuria and proteinuria. Renal biopsy revealed proliferative necrotizing IgAVN (ISKDC grade III) with diffuse podocyte foot-process effacement. Prednisone 30 mg/day for 6 days did not improve proteinuria (24-h urinary protein increased from 1.28 g to 1.44 g) and axial AS symptoms relapsed. Glucocorticoids were replaced with rituximab (RTX) 500 mg intravenously every 7–10 days for 4 infusions, with concomitant discontinuation of secukinumab.

Results

Four weeks after the first infusion, peripheral blood CD19+ B cells were completely depleted and 24-h urinary protein decreased to 0.83 g; at 6 months it was 0.06 g and remained negative, with serum albumin normalized. AS remained stable after IL-17A inhibitor withdrawal (BASDAI score of 0). One pulmonary infection occurred during RTX treatment and resolved with anti-infective therapy.

Conclusion

RTX may be an effective option for IgAVN with podocyte injury and inadequate glucocorticoid response in patients with AS, and may help maintain AS stability after IL-17A inhibitor discontinuation.

Zitieren

APA

Zhang, Y., Yu, Q., Liu, Y., Yuan, Y., & Yang, Y. (2026). Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.2011766

Vancouver

Zhang Y, Yu Q, Liu Y, Yuan Y, Yang Y. Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.2011766

BibTeX
@article{Zhang2026,
  author = {Zhang, Yangyang and Yu, Qi and Liu, Yan and Yuan, Yiyuan and Yang, Yanlang},
  title = {Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.2011766}
}
Kostenlos starten →